Treating for Stage III NSCLC After Progression on Durvalumab | OncLive
Treating for Stage III NSCLC After Progression on Durvalumab | Onc…
Jul 13, 2020
onclive.com
Durvalumab in Stage III NSCLC Based on Performance Status | OncLive
Durvalumab in Stage III NSCLC Based on Performance Status | On…
Jul 13, 2020
onclive.com
Dr. Langer on the Benefit of Durvalumab in Stage III NSCLC | OncLive
Dr. Langer on the Benefit of Durvalumab in Stage III NSCLC | O…
May 29, 2019
onclive.com
PACIFIC Trial: Durvalumab Following Chemotherapy for Stage III NSCLC | OncLive
PACIFIC Trial: Durvalumab Following Chemotherapy for Stag…
Jul 13, 2020
onclive.com
Places to see in ( Madrid - Spain ) Teatro Real
1:19
Places to see in ( Madrid - Spain ) Teatro Real
271 viewsSep 21, 2017
YouTubeplaces to see in
Association Between KRAS/STK11/KEAP1 Mutations and Outcomes in POSEIDON: Durvalumab ± Tremelimumab Chemotherapy in Metastatic NSCLC | OncLive
Association Between KRAS/STK11/KEAP1 Mutations an…
Aug 29, 2022
onclive.com
The HIMALAYA study investigated STRIDE (tremelimumab durvalumab) and durvalumab alone as alternatives to sorafenib for unresectable hepatocellular carcinoma. Results showed longer survival and better quality of life for patients receiving STRIDE or durvalumab. Learn more in our animated video article. https://bit.ly/3Rwhc08 #LiverCancer #HCC #Oncology #Cancer | Video Journal of Biomedicine
0:33
The HIMALAYA study investigated STRIDE (tremelimumab durvaluma…
17 views11 months ago
FacebookVideo Journal of Biomedicine
KRAS G12C Inhibition in Non-Small Cell Lung Cancer
Dec 19, 2020
findkrasg12c.com
How to Personalize the Treatment in Patients With KRAS G12C, KRAS …
491 viewsNov 3, 2022
vumedi.com
12:40
Real-world comparison of the efficacy and safety of atezolizuma…
Dec 17, 2024
onclive.com
3:04
Drift_Battle_III
1.7K viewsAug 20, 2009
mail.ruРодион 1
2:16
III этап, Дрифт, Красноярск
4.5K viewsAug 26, 2008
mail.ruРодион 1
Treatment Options for KRAS-Mutated NSCLC | AJMC
Jul 11, 2022
ajmc.com
WCLC 2024 Insights: PACIFIC-BRAZIL Study - Intensified Chem…
51 viewsSep 23, 2024
vumedi.com
2L KRAS Inhibitors for Patients With KRAS G12C–Mutated NSCLC | On…
2 weeks ago
onclive.com
ESMO 2024 Insights: HIMALAYA - 5-Year OS of Tremelimumab Durval…
223 viewsSep 20, 2024
vumedi.com
ASCO 2021 Updates from the PACIFIC Trial: Five-Year Survival …
268 viewsNov 11, 2021
vumedi.com
CStone Pharmaceuticals Limited Announces European Commissio…
3 months ago
marketscreener.com
1:45
Watch as Najeeb, MD, MS, and Sakti Chakrabarti, MD, share insights o…
30 viewsJan 20, 2025
FacebookOncLive
Treatment of KRAS G12C Mutant NSCLC
May 11, 2022
onclive.com
Durvalumab in LS-SCLC: Exploring Phase 3 ADRIATIC Trial Outcome…
4 weeks ago
onclive.com
What's Happening in KRAS G12C NSCLC? | OncLive
Apr 9, 2021
onclive.com
HIMALAYA Trial: First-Line Tremelimumab Plus Durvalumab I…
Oct 2, 2022
ascopost.com
9:17
Frontline Treatments for KRAS G12C-Mutation mNSCLC | OncLive
2 weeks ago
onclive.com
EMERALD-3: tremelimumab durvalumab with or without lenvat…
Sep 10, 2022
vjoncology.com
1:20
Sequencing KRAS-Targeted Therapy in G12C Mutated NSCLC …
Feb 21, 2024
targetedonc.com
Dr. Garon on Immunotherapy in Stage III Unresectable NSCLC | On…
3 weeks ago
onclive.com
KRAS, EGFR, and the Future of Lung Cancer Treatment
11 months ago
medscape.com
2:11
Sotorasib is approved in the United States to treat KRAS p.G12C–mut…
2.6K viewsJan 4, 2023
FacebookThe New England Journal of Medicine
Radiomic features predict local failure-free survival in stage III NS…
11 months ago
spiedigitallibrary.org
See more videos
Static thumbnail place holder